I
Ikano Therapeutics
Developing digital health tools to help researchers track patient data, analyze it, and export it for publication
About Ikano Therapeutics
Ikano Therapeutics, Inc., originally founded as Intranasal Therapeutics Inc. in 1998 by Edwin Cohen, operated as a specialty pharmaceutical company focused on developing and commercializing nasally delivered drug products. In March 2009, the company rebranded to Ikano Therapeutics, a name derived from the Greek word for "enable," to reflect a broader corporate strategy beyond intranasal delivery to a more diversified emphasis on high-impact specialty therapeutic products.
The company's primary focus was on addressing unmet medical needs in the treatment of pain and central nervous system disorders. A key asset in its pipeline was ITI-111, a nasally administered formulation of midazolam for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity, also known as cluster seizures, in epilepsy patients aged 12 and older. This product, which later became known as Nayzilam®, was developed as a more practical and acceptable outpatient alternative to existing treatments. In November 2009, Ikano received Orphan Drug designation for this midazolam formulation, a status that provides for seven years of marketing exclusivity.
Ikano Therapeutics successfully raised a total of $57.1 million over three funding rounds, including a Series A of $39.1 million in 2006 and a Series B round in 2009. The investor syndicate included prominent venture capital firms such as SV Health Investors (formerly SV Life Sciences), Tullis Health Investors, Burrill & Company, and F-Prime Capital (formerly Fidelity Biosciences). Following a strategic shift, Michael Ross of SV Life Sciences was appointed Chairman of the Board in 2009. Ultimately, Ikano Therapeutics was acquired by UCB, a global biopharmaceutical company. Reports indicate that Ikano went out of business as an independent entity around November 2010.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
Growth signals
Ikano Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Ikano Therapeutics in the Saddle Brook ecosystem
The Ikano Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Eight Roads Ventures
SV Health Investors- AVApjohn ventures
Burrill
Fort Washington Capital Partners
Commonwealth Seed Capital
Other known investors2 additional known investors
University of Kentucky
F-Prime
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ikano Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ikano Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










